Telmisartan inhibits NSCLC A549 cell proliferation and migration by regulating the PI3K/AKT signaling pathway

  • Authors:
    • Suolin Zhang
    • Yayan Wang
  • View Affiliations

  • Published online on: February 8, 2018     https://doi.org/10.3892/ol.2018.8002
  • Pages: 5859-5864
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Expression of angiotensin II (Ang II), a key biological peptide in the renin‑angiotensin system, is closely associated with the occurrence and development of cancer. Ang II binds two receptor subtypes, the Ang II type 1 receptor (AT1R) and the AT2R, to mediate a series of biological effects. Telmisartan, a specific AT1R blocker, has been reported to have potential as an anticancer drug for treating renal cancer. In the present study, whether telmisartan had an effect on non‑small cell lung cancer (NSCLC) cell proliferation and migration was investigated. The Cell Counting kit‑8 assay revealed that telmisartan significantly inhibited the growth of the NSCLC A549 cell line in a time‑ and dose‑dependent manner. In a transwell assay, telmisartan significantly inhibited cellular invasion and migration. Furthermore, it was determined that the expression of the anti‑apoptotic protein B‑cell lymphoma was decreased, and that of the pro‑apoptotic proteins caspase‑3 and Bcl‑associated X increased in the A549 cells treated with telmisartan. Additionally, levels of phosphorylated RAC serine/threonine‑protein kinase (p‑AKT), p‑mechanistic target of rapamycin, p70‑S6 kinase and cyclin D1 was decreased in the telmisartan‑treated group. Therefore, the current study reveals that telmisartan‑induced NSCLC apoptosis may be regulated via the phosphoinositide 3‑kinase/AKT signaling pathway, which indicates that it may be a potential novel drug for clinical NSCLC treatment.
View Figures
View References

Related Articles

Journal Cover

April-2018
Volume 15 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang S and Zhang S: Telmisartan inhibits NSCLC A549 cell proliferation and migration by regulating the PI3K/AKT signaling pathway. Oncol Lett 15: 5859-5864, 2018
APA
Zhang, S., & Zhang, S. (2018). Telmisartan inhibits NSCLC A549 cell proliferation and migration by regulating the PI3K/AKT signaling pathway. Oncology Letters, 15, 5859-5864. https://doi.org/10.3892/ol.2018.8002
MLA
Zhang, S., Wang, Y."Telmisartan inhibits NSCLC A549 cell proliferation and migration by regulating the PI3K/AKT signaling pathway". Oncology Letters 15.4 (2018): 5859-5864.
Chicago
Zhang, S., Wang, Y."Telmisartan inhibits NSCLC A549 cell proliferation and migration by regulating the PI3K/AKT signaling pathway". Oncology Letters 15, no. 4 (2018): 5859-5864. https://doi.org/10.3892/ol.2018.8002